Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardiff Oncology, Inc.TROV · Entity 6917 | Director | January 23, 2018 | January 25, 2018 |
| MetaStat, Inc.MTST · Entity 170270 | Director | October 11, 2017 | November 21, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardiff Oncology, Inc.
Report date January 23, 2018 · Filed January 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2028-01-23 | Direct | 175,658 |
Reported balance
After 2018-01-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-23 · Grant · Acquired 54,322 · Balance 175,658 |
MetaStat, Inc.
Report date October 11, 2017 · Filed November 21, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 50,000 |
Reported balance
After 2017-10-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-10-11 · Exercise / conversion · Acquired 50,000 · Balance 50,000 F1: Each restricted stock unit represents a contingent right to receive, at settlement, one share of the Company's common stock. F2: The restricted stock units were granted on October 11, 2017 and will vest for active service as follows: (a) 12,500 shares on January 11, 2018, (b) 12,500 shares on April 11, 2018, (c) 12,500 shares on July 11, 2018, and (d) 12,500 shares on October 11, 2018. Vested restricted stock units settle on the October 11, 2020, unless accelerated due to departure from the Company's board of directors or a change of control. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive, at settlement, one share of the Company's common stock.
F2: The restricted stock units were granted on October 11, 2017 and will vest for active service as follows: (a) 12,500 shares on January 11, 2018, (b) 12,500 shares on April 11, 2018, (c) 12,500 shares on July 11, 2018, and (d) 12,500 shares on October 11, 2018. Vested restricted stock units settle on the October 11, 2020, unless accelerated due to departure from the Company's board of directors or a change of control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2018 Filed Jan 25, 2018 22:02 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantStock Options · Derivative | 54,322 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0000899243-18-001906 · doc4.xml · derivative · entry 1 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,658 Underlying: Common Stock · 54,322 shares Expires 2028-01-23 Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:16 UTC Amendment | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000531 · doc4a.xml · derivative · entry 2 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 5, 2018 01:16 UTC Amendment | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000531 · doc4a.xml · nonDerivative · entry 1 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:16 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000484 · doc4.xml · derivative · entry 2 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. The common stock into which such vested restricted stock units converted on January 2, 2018 is reported in Table I on this Form 4. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 22:16 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-000484 · doc4.xml · nonDerivative · entry 1 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 16,667 restricted stock units, all of which vested on January 2, 2018. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017. Read SEC document |
| October 11, 2017 Filed Nov 21, 2017 19:53 UTC | MetaStat, Inc. MTST · Entity 170270 | Exercise / conversionRestricted Stock Unit · Derivative | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-17-001842 · form4-11212017_041156.xml · derivative · entry 1 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive, at settlement, one share of the Company's common stock. F1 · price: Each restricted stock unit represents a contingent right to receive, at settlement, one share of the Company's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on October 11, 2017 and will vest for active service as follows: (a) 12,500 shares on January 11, 2018, (b) 12,500 shares on April 11, 2018, (c) 12,500 shares on July 11, 2018, and (d) 12,500 shares on October 11, 2018. Vested restricted stock units settle on the October 11, 2020, unless accelerated due to departure from the Company's board of directors or a change of control. F2 · derivative.expiration_date: The restricted stock units were granted on October 11, 2017 and will vest for active service as follows: (a) 12,500 shares on January 11, 2018, (b) 12,500 shares on April 11, 2018, (c) 12,500 shares on July 11, 2018, and (d) 12,500 shares on October 11, 2018. Vested restricted stock units settle on the October 11, 2020, unless accelerated due to departure from the Company's board of directors or a change of control. Read SEC document |
| October 04, 2017 Filed Oct 5, 2017 20:18 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantStock Options · Derivative | 38,106 | $0.00 Strike: $0.72 | $0.00 |
DisclosureSEC source: 0001104659-17-061151 · a4.xml · derivative · entry 1 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,336 Underlying: Common Stock · 38,106 shares Expires 2027-10-04 Read SEC document |
| September 02, 2017 Filed Sep 7, 2017 00:48 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionRestricted Stock Units · Derivative | 6,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-055893 · a4.xml · derivative · entry 2 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 6,498 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: On January 2, 2017, the reporting person was granted 6,498 restricted stock units, all of which vested on September 2, 2017. The common stock into which such vested restricted stock units converted on September 2, 2017 is reported in Table I on this Form 4. F3 · derivative.expiration_date: On January 2, 2017, the reporting person was granted 6,498 restricted stock units, all of which vested on September 2, 2017. The common stock into which such vested restricted stock units converted on September 2, 2017 is reported in Table I on this Form 4. Read SEC document |
| September 02, 2017 Filed Sep 7, 2017 00:48 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | Exercise / conversionCommon Stock | 6,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-055893 · a4.xml · nonDerivative · entry 1 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock (the "Converted Common Stock"). On January 2, 2017, the reporting person was granted 6,498 restricted stock units, all of which vested on September 2, 2017. Such restricted stock units were previously reported in Table II on a Form 4 filed with the Securities and Exchange Commission on January 5, 2017. Read SEC document |
| January 02, 2017 Filed Jan 4, 2017 22:01 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000631 · a4.xml · derivative · entry 1 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F2 · derivative.exercise_date: The RSUs shall vest on January 2, 2018. F2 · derivative.expiration_date: The RSUs shall vest on January 2, 2018. Read SEC document |
| January 02, 2017 Filed Jan 5, 2017 21:59 UTC Amendment | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantRestricted Stock Units · Derivative | 6,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000964 · a4a.xml · derivative · entry 2 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,165 Underlying: Common Stock · 6,498 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F3 · derivative.exercise_date: The RSUs shall vest on September 2, 2017 F3 · derivative.expiration_date: The RSUs shall vest on September 2, 2017 Read SEC document |
| January 02, 2017 Filed Jan 5, 2017 21:59 UTC Amendment | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantRestricted Stock Units · Derivative | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-000964 · a4a.xml · derivative · entry 1 Billings Paul · CIK 0001591558 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit is the economic equivalent of one share of Trovagene, Inc. common stock. F2 · derivative.exercise_date: The RSUs shall vest on January 2, 2018. F2 · derivative.expiration_date: The RSUs shall vest on January 2, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.